JP2017507945A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507945A5 JP2017507945A5 JP2016554212A JP2016554212A JP2017507945A5 JP 2017507945 A5 JP2017507945 A5 JP 2017507945A5 JP 2016554212 A JP2016554212 A JP 2016554212A JP 2016554212 A JP2016554212 A JP 2016554212A JP 2017507945 A5 JP2017507945 A5 JP 2017507945A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- hvr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 182
- 238000000034 method Methods 0.000 claims description 94
- 101000863884 Homo sapiens Sialic acid-binding Ig-like lectin 8 Proteins 0.000 claims description 86
- 102000051056 human SIGLEC8 Human genes 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 51
- 208000024891 symptom Diseases 0.000 claims description 51
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 39
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 39
- 239000000556 agonist Substances 0.000 claims description 35
- 208000038004 exacerbated respiratory disease Diseases 0.000 claims description 30
- 230000001771 impaired effect Effects 0.000 claims description 25
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 21
- 229930182474 N-glycoside Natural products 0.000 claims description 21
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 21
- 206010011224 Cough Diseases 0.000 claims description 20
- 150000001720 carbohydrates Chemical group 0.000 claims description 20
- 230000007794 irritation Effects 0.000 claims description 20
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 19
- 208000006673 asthma Diseases 0.000 claims description 19
- 102100029964 Sialic acid-binding Ig-like lectin 8 Human genes 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 206010003645 Atopy Diseases 0.000 claims description 16
- 230000003915 cell function Effects 0.000 claims description 16
- 208000000592 Nasal Polyps Diseases 0.000 claims description 15
- 206010036790 Productive cough Diseases 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 208000024794 sputum Diseases 0.000 claims description 15
- 210000003802 sputum Anatomy 0.000 claims description 15
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 210000003979 eosinophil Anatomy 0.000 claims description 13
- 208000015768 polyposis Diseases 0.000 claims description 13
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 12
- 208000010753 nasal discharge Diseases 0.000 claims description 12
- 208000028347 Sinus disease Diseases 0.000 claims description 11
- 201000010659 intrinsic asthma Diseases 0.000 claims description 11
- 206010014950 Eosinophilia Diseases 0.000 claims description 9
- 210000000822 natural killer cell Anatomy 0.000 claims description 9
- 230000002085 persistent effect Effects 0.000 claims description 9
- 206010006326 Breath odour Diseases 0.000 claims description 8
- 206010016059 Facial pain Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 206010028735 Nasal congestion Diseases 0.000 claims description 8
- 206010052437 Nasal discomfort Diseases 0.000 claims description 8
- 206010028748 Nasal obstruction Diseases 0.000 claims description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 8
- 208000032140 Sleepiness Diseases 0.000 claims description 8
- 206010041349 Somnolence Diseases 0.000 claims description 8
- 208000027744 congestion Diseases 0.000 claims description 8
- 208000002173 dizziness Diseases 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 208000004371 toothache Diseases 0.000 claims description 8
- 208000037874 Asthma exacerbation Diseases 0.000 claims description 7
- 102000003886 Glycoproteins Human genes 0.000 claims description 7
- 108090000288 Glycoproteins Proteins 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 208000016366 nasal cavity polyp Diseases 0.000 claims description 7
- 229920001542 oligosaccharide Polymers 0.000 claims description 7
- 150000002482 oligosaccharides Chemical class 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 150000003431 steroids Chemical class 0.000 claims description 7
- 230000009885 systemic effect Effects 0.000 claims description 7
- 208000032139 Halitosis Diseases 0.000 claims description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 6
- 206010025482 malaise Diseases 0.000 claims description 6
- 230000035945 sensitivity Effects 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- 208000020685 sleep-wake disease Diseases 0.000 claims description 6
- 206010011703 Cyanosis Diseases 0.000 claims description 4
- 208000000059 Dyspnea Diseases 0.000 claims description 4
- 206010013975 Dyspnoeas Diseases 0.000 claims description 4
- 208000037656 Respiratory Sounds Diseases 0.000 claims description 4
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 4
- 206010047924 Wheezing Diseases 0.000 claims description 4
- 208000013116 chronic cough Diseases 0.000 claims description 4
- 208000013220 shortness of breath Diseases 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- 206010008469 Chest discomfort Diseases 0.000 claims description 3
- 230000000779 depleting effect Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 230000020279 natural killer cell cytokine production Effects 0.000 claims description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 206010014020 Ear pain Diseases 0.000 claims 4
- 206010070488 Upper-airway cough syndrome Diseases 0.000 claims 4
- 230000037418 vocal dysfunction Effects 0.000 claims 4
- 238000013313 FeNO test Methods 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- 206010003497 Asphyxia Diseases 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 230000004199 lung function Effects 0.000 claims 1
- 238000013123 lung function test Methods 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 238000013125 spirometry Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 230000001270 agonistic effect Effects 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946407P | 2014-02-28 | 2014-02-28 | |
| US61/946,407 | 2014-02-28 | ||
| PCT/US2015/018188 WO2015131155A1 (en) | 2014-02-28 | 2015-02-27 | Methods and compositions for treating siglec-8 associated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021003944A Division JP2021054866A (ja) | 2014-02-28 | 2021-01-14 | シグレック−８関連疾患を処置するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017507945A JP2017507945A (ja) | 2017-03-23 |
| JP2017507945A5 true JP2017507945A5 (cg-RX-API-DMAC7.html) | 2018-04-12 |
| JP6825909B2 JP6825909B2 (ja) | 2021-02-03 |
Family
ID=54009691
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016554212A Active JP6825909B2 (ja) | 2014-02-28 | 2015-02-27 | シグレック−８関連疾患を処置するための方法および組成物 |
| JP2021003944A Pending JP2021054866A (ja) | 2014-02-28 | 2021-01-14 | シグレック−８関連疾患を処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021003944A Pending JP2021054866A (ja) | 2014-02-28 | 2021-01-14 | シグレック−８関連疾患を処置するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10183996B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4014995A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6825909B2 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015222757B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2939931C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3110446T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015131155A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2758508T3 (es) * | 2013-12-09 | 2020-05-05 | Allakos Inc | Anticuerpos dirigidos contra Siglec-8 y métodos de uso de los mismos |
| AU2015222757B2 (en) | 2014-02-28 | 2020-10-08 | Allakos Inc. | Methods and compositions for treating Siglec-8 associated diseases |
| CA2987797A1 (en) * | 2015-06-17 | 2016-12-22 | Christopher Robert Bebbington | Methods and compositions for treating fibrotic diseases |
| US10604577B2 (en) * | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| JP2020504135A (ja) * | 2017-01-06 | 2020-02-06 | アラコス インコーポレイテッド | 慢性閉塞性肺障害を処置するための方法および組成物 |
| CN110831628A (zh) * | 2017-05-05 | 2020-02-21 | 爱乐科斯公司 | 用于治疗过敏性眼病的方法和组合物 |
| KR20200015511A (ko) * | 2017-05-05 | 2020-02-12 | 알라코스 인크. | 염증성 위장 장애를 치료하기 위한 방법 및 조성물 |
| US12226492B2 (en) | 2017-12-29 | 2025-02-18 | Cornell University | Gene therapy for eosinophilic disorders |
| KR102417088B1 (ko) * | 2018-02-09 | 2022-07-07 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
| MX2020011377A (es) * | 2018-05-04 | 2020-11-24 | Allakos Inc | Metodos y composiciones para el tratamiento de urticaria cronica. |
| WO2020179700A1 (ja) * | 2019-03-01 | 2020-09-10 | 国立大学法人筑波大学 | アレルギー疾患を処置することに用いるための組成物 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| WO1997038123A1 (en) | 1996-04-05 | 1997-10-16 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
| DE19619068A1 (de) | 1996-05-13 | 1997-11-27 | Siemens Ag | Vorrichtung zur Überwachung des Transportprozesses von flachen Sendungen |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| PT994903E (pt) | 1997-06-24 | 2005-10-31 | Genentech Inc | Metodos e composicoes para glicoproteinas galactosiladas |
| EP1028751B1 (en) | 1997-10-31 | 2008-12-31 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| EP1034298B1 (en) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanization of murine antibody |
| EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| WO2001066126A1 (en) * | 2000-03-07 | 2001-09-13 | Smithkline Beecham Corporation | Sialoadhesin factor-2 antibodies |
| US20030092091A1 (en) | 2000-03-07 | 2003-05-15 | Abrahamson Julie A. | Sialoadhesin factor-2 antibodies |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US20020106738A1 (en) | 2000-10-06 | 2002-08-08 | George Foussias | Novel Siglec gene |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| RU2321630C2 (ru) | 2001-08-03 | 2008-04-10 | Гликарт Биотекнолоджи АГ | Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
| PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| US7749753B2 (en) | 2002-04-09 | 2010-07-06 | Kyowa Hakko Kirin Co., Ltd | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004056312A2 (en) | 2002-12-16 | 2004-07-08 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
| WO2005035778A1 (ja) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法 |
| RS55723B1 (sr) | 2003-11-05 | 2017-07-31 | Roche Glycart Ag | Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| EP2990053A1 (en) | 2004-01-20 | 2016-03-02 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| WO2005116088A2 (en) * | 2004-05-25 | 2005-12-08 | The Johns Hopkins University | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells |
| CA2587158C (en) | 2004-11-16 | 2016-01-12 | Kalobios, Inc. | Immunoglobulin variable region cassette exchange |
| EP1951740B1 (en) | 2005-11-10 | 2014-07-16 | James Paulson | High affinity siglec ligands |
| WO2007056870A1 (en) | 2005-11-21 | 2007-05-24 | The Governors Of The University Of Alberta | Methods and compositions for pharmacologically controlled targeted immunotherapy |
| NZ597251A (en) | 2006-05-30 | 2013-08-30 | Genentech Inc | Antibodies and immunoconjugates and uses therefor |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| AU2008255352B2 (en) | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| EP2282773B2 (en) | 2008-05-02 | 2025-03-05 | Seagen Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| EP3153524B1 (en) | 2008-12-03 | 2025-04-23 | Genmab A/S | Antibody variants having modifications in the constant region |
| MX2012002427A (es) | 2009-08-28 | 2012-08-03 | Vlst Corp | Anticuerpos anticina que se unen a quimiocinas cc multiples. |
| BR112012006388B1 (pt) | 2009-09-22 | 2022-01-04 | Probiogen Ag | Método para produzir uma molécula, e, método para produzir uma proteína |
| CA2800769C (en) | 2010-05-27 | 2021-11-02 | Genmab A/S | Monoclonal antibodies against her2 epitope |
| US8586044B2 (en) | 2010-05-28 | 2013-11-19 | Northwestern University | Treatment of chronic pelvic pain syndrome |
| EP2465873A1 (en) * | 2010-12-16 | 2012-06-20 | Deutsches Rheuma-Forschungszentrum Berlin | Eosinophils as a therapeutic target |
| AU2013222129B2 (en) | 2012-02-24 | 2018-02-15 | Children's Hospital Medical Center | Esophageal microRNA expression profiles in eosinophilic esophagitis |
| KR20150044680A (ko) | 2013-10-17 | 2015-04-27 | 인하대학교 산학협력단 | 항-Siglec-8 항체 또는 항-Siglec-F 항체를 포함하는 알러지 질환의 예방 또는 치료용 조성물 |
| KR101567758B1 (ko) | 2013-10-17 | 2015-11-11 | 인하대학교 산학협력단 | 항-Siglec-8 항체 또는 항-Siglec-F 항체, 및 항-IL-33 항체를 포함하는 알러지 질환의 예방 또는 치료용 조성물 |
| ES2758508T3 (es) | 2013-12-09 | 2020-05-05 | Allakos Inc | Anticuerpos dirigidos contra Siglec-8 y métodos de uso de los mismos |
| AU2015222757B2 (en) | 2014-02-28 | 2020-10-08 | Allakos Inc. | Methods and compositions for treating Siglec-8 associated diseases |
| CA2987797A1 (en) | 2015-06-17 | 2016-12-22 | Christopher Robert Bebbington | Methods and compositions for treating fibrotic diseases |
| US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| JP2020504135A (ja) | 2017-01-06 | 2020-02-06 | アラコス インコーポレイテッド | 慢性閉塞性肺障害を処置するための方法および組成物 |
-
2015
- 2015-02-27 AU AU2015222757A patent/AU2015222757B2/en active Active
- 2015-02-27 EP EP21204280.8A patent/EP4014995A1/en not_active Withdrawn
- 2015-02-27 EP EP15755175.5A patent/EP3110446B1/en active Active
- 2015-02-27 US US15/121,756 patent/US10183996B2/en active Active
- 2015-02-27 WO PCT/US2015/018188 patent/WO2015131155A1/en not_active Ceased
- 2015-02-27 JP JP2016554212A patent/JP6825909B2/ja active Active
- 2015-02-27 CA CA2939931A patent/CA2939931C/en active Active
- 2015-02-27 DK DK15755175.5T patent/DK3110446T3/da active
-
2021
- 2021-01-07 AU AU2021200075A patent/AU2021200075A1/en not_active Abandoned
- 2021-01-14 JP JP2021003944A patent/JP2021054866A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507945A5 (cg-RX-API-DMAC7.html) | ||
| JP7695298B2 (ja) | Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法 | |
| AU2018253118B2 (en) | Treatment of asthma with anti-TSLP antibody | |
| CA2918105C (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| JP2018505177A5 (cg-RX-API-DMAC7.html) | ||
| JP2018525332A5 (cg-RX-API-DMAC7.html) | ||
| CN110799543A (zh) | 肝细胞癌的免疫治疗 | |
| CN104684552A (zh) | 组合及其用途 | |
| CN107108727A (zh) | 对人vegf‑a有异常强的结合亲和力并具有与人vegf‑b的交叉反应性的抗人vegf抗体 | |
| JP2025122028A (ja) | Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法 | |
| JP2018533569A5 (cg-RX-API-DMAC7.html) | ||
| EP3520811B1 (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| US20240092875A1 (en) | Sars-cov-2 antibodies for treatment and prevention of covid-19 | |
| JP2020504135A5 (cg-RX-API-DMAC7.html) | ||
| EP3033103B1 (en) | Methods for improving asthma symptoms using benralizumab | |
| AU2023278017A1 (en) | Combination therapies for the treatment of cancer | |
| JPWO2019169015A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2021026021A5 (cg-RX-API-DMAC7.html) | ||
| JP2018517667A5 (cg-RX-API-DMAC7.html) | ||
| AU2023278019A1 (en) | Combination therapies for the treatment of non-small cell lung cancer | |
| WO2024077113A1 (en) | Methods of treating fatigue in ulcerative colitis | |
| JPWO2022034044A5 (cg-RX-API-DMAC7.html) | ||
| JP2024542777A (ja) | 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎（ｃｒｓｗｎｐ）又は鼻ポリープを伴わない慢性副鼻腔炎（ｃｒｓｓｎｐ）の処置における使用のためのインターロイキン５結合タンパク質投与レジメン | |
| HK1225302A1 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| HK40035226A (en) | Methods for reducing exacerbation rates of asthma using benralizumab |